



ALIVIRA



Alivira's Animal Health API facility gets USFDA approval

First US FDA approval for an Indian Animal Health facility

Mumbai, May 2, 2017 - SeQuent Scientific Limited ("SeQuent") today announced that Alivira has received US FDA approval for its Animal Health API facility at Visakhapatnam, Andhra Pradesh.

This ~225KL capacity multi-product facility at Vizag was inspected for the first time by USFDA in November 2016 and has now received Establishment Inspection Report (EIR) from US FDA. The receipt of the EIR will enable Alivira's entry into \$8 billion US veterinary healthcare market.

Alivira is the largest animal health company from India with annual revenues of \$ 120 mn. It is also the largest animal health API manufacturer from India. Predominant in anthelmintic, the company has 16 products in the primary therapies across antibiotics, beta agonists, NSAID, antiprotozoal and feed additives. Over the last year, the Company has launched five new products and filed for 6 Veterinary Master Files (VMF). The Company also has a pipeline of over seven products at different stages at development.

Commenting on the development, **Mr. Manish Gupta, Managing Director of Alivira** said *"We are pleased with the USFDA approval for our animal health API facility, which is a critical milestone in our journey to build a global Animal health business out of India. While we are already working with most of the leading animal health companies' world over, this approval will enable us expand our reach and consolidate our relationship with these enterprises."*

Alivira's Vizag API facility is also in compliance with ISO 9001 (Quality Management systems) and ISO 14000 (Environment Management systems).

About Alivira Animal Health Limited

Alivira Animal Health Limited ("Alivira"), a wholly owned subsidiary of SeQuent is a vertically integrated Animal Healthcare company with six state of the art manufacturing facilities. The Company's API business is characterized by new product development capability, best-in-class infrastructure, wide product basket and long-term relationships with most of the global animal health companies. In the formulations space, Alivira has established business presence in India, Turkey, Europe, Latam, Africa, MENA and South East Asia. It has close to 200 dosage forms focused towards production animals produced in GMP compliant facilities in Spain, Turkey, Brazil and India. Alivira's long-term vision is to become a global powerhouse for animal health built on a platform of superior quality and compliance.

About SeQuent Scientific Limited

SeQuent Scientific Limited (BSE-512529, NSE-SEQUENT) is an integrated pharmaceutical company with a global footprint, operating in the domains of Animal Health (API and formulation), Human Health (API) and Analytical Services. Headquartered in Mumbai, India, SeQuent has nine manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from global regulatory bodies including USFDA, EUGMP, WHO, TGA among others.

For Queries, please contact

Tushar Mistry

Chief Financial Officer

Tel: +91 22 41114754

Tushar.m@sequent.in

Ankit Gupta

Christensen Investor Relations

Tel : +91 22 42150210

ankitgupta@christensenir.com

Registered Office

SeQuent Scientific Limited

301/A, 'Dosti Pinnacle', Plot No. E7, Road
No. 22, Wagle Industrial Area, Thane
(W), Maharashtra, India

CIN: L99999MH1985PLC036685

BSE Code:512529

ISIN: INE807F01019

REUTERS: SEQU.BO

Website: www.sequent.in

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Sequent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.